Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220008323Skin Moisturizing Formulation
US 13.01.2022
Int.Class A61K 8/92
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products
Appl.No 16922234 Applicant Tova Palomino Inventor Tova Palomino

A formulation of oils including, Simmondsia chinensis Seed Oil, Rosa moschata Seed Oil, Daucus carota Stavia Seed Oil, Callophyllum inophyllum Oil, Rosmarinus officinalis Leaf Oil, Boswellia carterii Oil, Pelargonium graveolens Oil, Cymbopogon fleuosus Oil, and Helichrysum italicum Oil. An example of the formulation's product is a cream, which can be applied to an individual's face and/or neck skin to provide benefits thereto.

2.20220008342COMBINATION TABLET WITH CHEWABLE OUTER LAYER
US 13.01.2022
Int.Class A61K 9/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
24Layered or laminated unitary dosage forms
Appl.No 17239319 Applicant Vitalis LLC Inventor Joseph Habboushe

A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.

3.20220008373COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS
US 13.01.2022
Int.Class A61K 31/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
235having an aromatic ring attached to a carboxyl group
24having an amino or nitro group
245Amino benzoic acid types, e.g. procaine, novocaine
Appl.No 17372158 Applicant Mark Loveless Inventor Mark Loveless

The present invention is directed to compositions, methods for preventing, treating and/or curing respiratory infections, such as infections caused by a coronavirus.

4.20220008458TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE
US 13.01.2022
Int.Class A61K 33/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
30Zinc; Compounds thereof
Appl.No 17365695 Applicant American Regent, Inc. Inventor Gopal Anyarambhatla

Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 μg to about 4,000 μg of zinc, about 40 μg to about 400 μg of copper, from about 4 μg to about 90 μg of selenium, or from about 1 μg to about 80 μg of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

5.20220008542ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF
US 13.01.2022
Int.Class A61K 47/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Appl.No 17487078 Applicant AUBURN UNIVERSITY Inventor Sue H. DURAN

The present disclosure provides veterinary formulations comprising a therapeutically effective amount of an antiprotozoal compound and a polymer. The disclosure also provides methods of treating trichomoniasis in a bovine and methods of treating a Tritrichomonas foetus infection in a bovine utilizing the veterinary formulations.

6.20220008460TREATING MALE INFERTILITY SECONDARY TO SPERM OXIDATIVE STRESS
US 13.01.2022
Int.Class A61K 33/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
30Zinc; Compounds thereof
Appl.No 17476801 Applicant Parviz Gharagozloo Inventor Parviz Gharagozloo

A profertility composition for administration to infertile men with sperm oxidative stress is disclosed. The composition comprises a unique combination of a pharmaceutically acceptable vitamin E, vitamin D, vitamin C, selenium, zinc, folate, lycopene, at least one carnitine source, and optionally Coenzyme Q10. Also disclosed are methods of treating male infertility.

7.20220009916ACETYLATION WRITER INHIBITOR DEVELOPMENT AND USES THEREOF
US 13.01.2022
Int.Class C07D 413/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
Appl.No 17289662 Applicant DANA-FARBER CANCER INSTITUTE, INC. Inventor Jun Qi

Disclosed are bifunctional compounds (degraders) that target HAT EP300 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

8.WO/2022/006636COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA (OSA)
WO 13.01.2022
Int.Class A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Appl.No PCT/AU2021/050734 Applicant INCANNEX HEALTHCARE LIMITED Inventor BLEACKLEY, Mark Robert
The present disclosure relates generally to compositions comprising Δ-9-tetrahydrocannabinol (THC) and a carbonic anhydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). In a particular embodiment, the treatment method comprises administering dronabinol and acetazolamide and combinations thereof to a subject in need.
9.WO/2022/007341FACE CLEANSING COMPOSITION CONTAINING AMINO ACID SURFACTANTS
WO 13.01.2022
Int.Class A61K 8/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
02characterised by special physical form
Appl.No PCT/CN2020/138340 Applicant BEIERSDORF AG Inventor DU, Heliang
The present invention relates to a cosmetic cleansing composition comprising an amino acid surfactant system consisting of sodium alkyl glycinate and potassium alkyl glycinate, and glycerol in an amount greater than 25 %by weight, referring to the total weight of the composition. The composition has a consistency being adapted to an easy dispensing from a tube, has a good cleansing efficiency and foam performance, and is still mild to the skin.
10.WO/2022/007461IMMUNOMODULATOR
WO 13.01.2022
Int.Class C07D 409/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Appl.No PCT/CN2021/087548 Applicant HITGEN INC. Inventor LI, Jin
Disclosed is an immunomodulator, and the present invention specifically relates to a compound for inhibiting IL-17A and an application of the compound serving as the immunomodulator in the preparation of a drug. Disclosed is an application of a compound represented by formula I or a stereoisomer thereof in preparing a drug for inhibiting IL-17A, and a new choice for clinically screening and/or preparing a drug for treating diseases related to IL-17A activity is provided.